Establishment and characterization of a cell-line originated from human mucinous cystadenocarcinoma of the ovary
Tóm tắt
We recently established a cell line (designated 371M) derived from an ovarian mucinous cystadenocarcinoma. The tumor cells were obtained from the ascitic fluid of a 54-year-old Japanese woman while she was undergoing surgery. Adjuvant chemotherapy (combined paclitaxel and carboplatin) was administered, but was ineffective, and she died about 4 months after surgery. The 371M cells continuously propagated in vitro over a period of about 50 months and, to date, have undergone over 100 passages. They proliferated in a monolayered sheet with doubling times of 84 h and 37 h in the 10th and 34th passages, respectively. When transplanted into nude mice, the tumor histopathologically resembled the structure of the original tumor. The 371M cells secreted high levels of CA125 and CA19-9 into the culture medium. There were several abnormal chromosomes in all karyotypes selected at random. Sensitivity of 371M cells to a variety of anti-cancer drugs was examined by in vitro MTT assay, and the results suggested that CPT-11 and CDDP were more effective against 371M cells than other anti-cancer agents.
Tài liệu tham khảo
Malcolm C, Monaghan J, Morrow C, et al: Pathology of malignant and borderline epithelial tumors of ovary. Gynecoligic Oncology vol.2, 2nd edition: Churchill Livingstone, London, UK: 1992, 871–876.
Tanba A, Ii K, Umeda M, et al: Techniques of tissue culture, 3rd edition: Asakura Shoten, Japan: 1996, 32–98.
Fushiki H, Hidaka T, Fujimura M, et al: Characterization of a Newly Established Human Tumor Cell Line (TEN) from a Patient with Clear Cell Carcinoma of the Uterine Body and its Sensitivity to Anti-cancer Agents. HUMAN CELL 10(3): 199–208, 1997.
Taylor CG, Sargent JM, Williamson CJ, et al: Chemosensitivity testing predicts survival in ovarian cancer. Eur J Gynecol Oncol 22(4): 278–282, 2001.
Benjamin RS: Pharmacokinetics of adoriamycin(NSC-123127) in patients with sarcomas. Cancer Chemother Rep. 58: 271–273, 1974.
Fujita H: Studies on concentration of bleomycin in blood, uterine and tissures. Chemotherapy 17, 933–937, 1969.
Elferink F, Van Der Vijgh W, Klein I, et al: Pharmacokinetics of carboplatin after iv administration. Cancer Treat. Rep. 71: 1231–1237, 1987.
Vermorken J, Van Der Vijgh W, Klein I, et al: Pharmacokinetics of free platinum species following rapid, 3-hr and 24-hr infusions of cis-diamminedichloroplatinum(II) and its therapeutic implications. Eur J Cancer Clin Oncol 18: 1069–1074, 1982.
Fujimura M, Kataoka T, Hidaka T, et al: Chemosensitivity test for human ovarian clear cell carcinoma. Oncol & Chemo 16(3): 241–244, 2000.
Kikuchi K, Kanno H: Comparison for blood levels and clinical effects between tablet and other dosage forms of 5-fluorouracil. Japan J Cancer Chemo 6: 559–565, 1979.
Fujita H: Pharmacokinetics of mitomycinC (MMC) and 7-N-(p-hydroxypheny1)-mitimycinC (KW-2083). J Cancer Chemo 9: 1362–1373, 1982.
Maehara Y, Oki E, Tokunaga E, et al: The present status of chemosensitivity test, 1st edition: Iyaku Journal Sha, Japan: 1999, 13–16.
Yamada T, Ueda M, Otsuki Y, et al: Establishment and characterization of a cell line(OMC-3) originating from a human mucinous cystadenocarcinoma of the ovary. Gynecol Oncol 40: 118–128. 1991.
Konishi I, Shimizu M: Pathology and prognosis in ovarian carcinoma. Sanfujinnka Chiryo 80: 178–182, 2000.
Sakai M, Nozawa S, Udagawa Y, et al: Bio-logical properties of two newly established cell lines (RMUG-S, RMUG-L) from a human ovarian mucinous cystadenocarcinoma. HUMAN CELL 3(1): 52–56, 1990.
Briers T, Stroobants P, Vandeputte T, et al: Establishment and characterization of a human ovarian neoplastic cell lie, DO-s. Cancer Res 49: 5153–5161, 1989.
Hayakawa O, Tsumura N, Koizumi M, et al: Establishment and characterization of cell line derived from mucinous cystadenocarcinoma of human ovary. Sapporo Med J 55: 153–160, 1986.
Miotti S, Aguanno S, Canevari S, et al: Biochemical analysis of human ovarian cancer associated antigens defined by murine monoclonal antibodies. Cancer Res 45: 826–832, 1985.
Kidera Y, Yoshimura T, Ohkuma Y, et al: Establishment and characterization of cell line derived from mucinous cystadenocarcinoma of human ovary. Acta Obstet Gynecol Jpn 37: 1820–1824, 1985.
Kiguchi K, Ishikawa I, Tokieda Y, et al: Establishment and Characterization of Human Uterine Pooly Differentiated Adenocarcinoma Cell Line (HHUABM). HUMAN CELL 12(4): 211–217, 1999.
Takeshima Y, Inai K: Mutations of gene in mucinous adenocarcinoma of the ovary. Acta Histochemica et Cytochemica(0044-5991) 33(2): 123–129, 2000.
Fujita M, Enomoto T, Inoue M, et al: Alteration of the p53 tumor suppressor gene occurs independently of k-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary. Jpn J Cancer Res 85(12): 1247–1256, 1994.
Teneriello MG, Ebina M, Linnoila RI, et al: p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res 53: 3103–3108, 1993.
Ling C: EstAblishment and characterization of cisplatin(CDDP)-resistant subclones delivered from human ovarian and cervical cancer cell limes. Sanpu no Shinpo 53(2): 99–109, 2001.
Niimi S, Yokoyama S, Tanaka T Establishment of Subclones Resisted to CDDP and Analysis of Their Mechanisms of Torelance. Oncol & Chemo 14(2): 127–131, 1998.
Udagawa Y, Nakada S, Nozawa S: Chemosensitivity test. Comprehensive Handbook of Women’s Medicine 36, 1st edition: Nakayama Shoten, Japan: 2000, 71–79.
Kubota T: Cancer Chemosensitivity Test -from laboratory to clinic. HUMANN CELL 8(4): 189–194, 1995.